CA
NZ
UK
AU
IND
US
…
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Xenetic Biosciences is a small, publicly listed clinical-stage biotechnology company with limited publicly available information indicating a focus on oncology and therapeutic delivery technologies. Long-term growth drivers include clinical advancement of development candidates, licensing or collaboration deals that commercialize platform technology, and regulatory approvals that could support revenue generation. Investors may find the company attractive for exposure to early-stage biotech upside if programs progress.
The most important risks are typical of small clinical-stage biotechs: high clinical and regulatory failure risk, ongoing financing and liquidity constraints, and limited operating history.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
| Net income | -2.68M | -3.96M | -4.13M | -6.39M | -5.54M |
| Selling general administrative | 2.75M | 3.42M | 3.56M | 3.65M | 3.74M |
| Gross profit | 2.98M | 2.50M | 2.54M | 1.68M | 1.13M |
| Reconciled depreciation | - | - | 0.00M | 0.03M | 0.04M |
| Ebit | - | -3.96M | -4.49M | -6.72M | -5.75M |
| Ebitda | -2.68M | -3.81M | -4.52M | -6.69M | -5.71M |
| Depreciation and amortization | - | 0.15M | -0.03M | 0.03M | 0.04M |
| Operating income | -2.83M | -4.20M | -4.52M | -6.72M | -5.75M |
| Other operating expenses | 5.81M | 6.70M | 7.06M | 8.42M | 6.91M |
| Interest expense | - | - | - | 0.17M | 0.10M |
| Tax provision | - | - | - | - | 0.00M |
| Interest income | 0.15M | 0.25M | 0.35M | 0.17M | 0.10M |
| Net interest income | 0.15M | 0.25M | 0.35M | 0.17M | 0.10M |
| Income tax expense | - | - | 0.03M | -0.17M | -0.10M |
| Total revenue | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| Total operating expenses | 5.81M | 6.70M | 7.06M | 8.42M | 6.91M |
| Cost of revenue | - | - | - | 0.03M | 0.04M |
| Total other income expense net | 0.15M | 0.24M | 0.38M | 0.17M | 0.10M |
| Net income from continuing ops | -2.68M | -3.96M | -4.45M | -6.55M | -5.65M |
| Net income applicable to common shares | - | - | - | - | -5.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 8.36M | 6.90M | 10.61M | 14.72M | 19.82M |
| Other current assets | 0.17M | 0.42M | 0.60M | 0.56M | 0.48M |
| Total liab | 0.97M | 0.89M | 0.81M | 1.07M | 1.42M |
| Total stockholder equity | 7.40M | 6.01M | 9.80M | 13.65M | 18.39M |
| Other current liab | 0.71M | 0.61M | 0.57M | 0.79M | 1.06M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.02M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.02M | 0.02M |
| Retained earnings | -199.88M | -197.19M | -193.23M | -189.10M | -182.55M |
| Other assets | - | - | - | - | 1.09M |
| Cash | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Total current liabilities | 0.97M | 0.89M | 0.81M | 1.07M | 1.42M |
| Net debt | -7.88M | -6.17M | -8.98M | -13.10M | -18.24M |
| Other stockholder equity | 207.01M | 202.94M | 202.77M | 202.48M | 200.67M |
| Total current assets | 8.05M | 6.59M | 9.59M | 13.65M | 18.72M |
| Net tangible assets | - | - | - | - | 18.39M |
| Accounts payable | 0.26M | 0.28M | 0.24M | 0.29M | 0.36M |
| Accumulated other comprehensive income | 0.25M | 0.25M | 0.25M | 0.25M | 0.25M |
| Non currrent assets other | 0.31M | 0.31M | 1.02M | 1.07M | 1.09M |
| Non current assets total | 0.31M | 0.31M | 1.02M | 1.07M | 1.09M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | 0.00M | -0.50M | 0.00M |
| Change to liabilities | - | - | - | - | 0.46M |
| Total cash from financing activities | 4.00M | 0.00M | 0.00M | 1.29M | 11.45M |
| Change to operating activities | - | - | - | - | 0.00M |
| Net income | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
| Change in cash | 1.72M | -2.82M | -4.11M | -5.15M | 6.72M |
| Begin period cash flow | 6.17M | 8.98M | 13.10M | 18.24M | 11.53M |
| End period cash flow | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Total cash from operating activities | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Issuance of capital stock | 4.00M | 0.00M | - | 0.00M | 11.45M |
| Depreciation | - | - | 0.00M | 0.03M | 0.04M |
| Sale purchase of stock | - | - | - | 1.29M | - |
| Other cashflows from financing activities | 4.00M | - | -0.00M | -0.50M | 0.00M |
| Change to netincome | - | - | - | - | 0.41M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.50M | 0.00M |
| Change in working capital | 0.33M | 0.97M | -0.26M | -0.43M | 0.46M |
| Stock based compensation | 0.06M | 0.17M | 0.28M | 0.51M | 0.41M |
| Other non cash items | 0.33M | 0.97M | 0.55M | 1.79M | 0.02M |
| Free cash flow | -2.29M | -2.82M | -4.11M | -5.15M | -4.74M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| XBIO Xenetic Biosciences Inc |
0.00 0.20% |
1.87 | - | - | 3.07 | 1.64 | 1.07 | 1.03 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jeffrey F. Eisenberg Esq. | CEO, Pres & Director | 1966 |
| Mr. James F. Parslow | CFO, COO & Corp. Sec. | 1965 |
| Dr. Curtis A. Lockshin | Chief Scientific Officer | 1960 |
| Mr. Jeffrey F. Eisenberg Esq. | CEO, President & Director | 1966 |
| Mr. James F. Parslow | CFO, COO & Corporate Secretary | 1965 |
| Mr. James F. Parslow | CFO, COO, Interim CEO & Corporate Secretary | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...